Company intelligence / Profile preview
Venatorx Pharmaceuticals
- Ownership
- Private
- Development stage
- NDA
Overview
Venatorx’s lead program, cefepime-taniborbactam—a beta-lactam/beta-lactamase inhibitor combination—has completed Phase 3 trials for cUTI and has an NDA under FDA review. The company also has an oral BL/BLI antibacterial in global Phase 3 trials and several preclinical programs targeting both bacterial resistance mechanisms and viral pathogens. The pipeline includes novel PBP inhibitors with the potential to overcome decades of antibiotic resistance. Recent partnerships include licensing agreements with Melinta Therapeutics for U.S. commercialization of cefepime-taniborbactam.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small molecules (notably beta-lactamase inhibitors and penicillin-binding protein inhibitors)
- Industry
- Biotech
Drug pipeline
11 assets10 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Venatorx Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Venatorx Pharmaceuticals.